Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
McKinsey
Mallinckrodt
Moodys

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR FLUORODOPA F18


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Fluorodopa F18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00674440 ↗ Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Completed University of Pennsylvania Phase 2 2004-12-01 Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.
NCT00674440 ↗ Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Completed Children's Hospital of Philadelphia Phase 2 2004-12-01 Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.
NCT01165632 ↗ Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting National Cancer Institute (NCI) Early Phase 1 2010-07-26 RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma
NCT01165632 ↗ Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting Mayo Clinic Early Phase 1 2010-07-26 RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma
NCT01991977 ↗ 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy Active, not recruiting National Cancer Institute (NCI) Phase 2 2013-12-01 This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
NCT01991977 ↗ 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy Active, not recruiting Mayo Clinic Phase 2 2013-12-01 This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluorodopa F18

Condition Name

Condition Name for Fluorodopa F18
Intervention Trials
Malignant Glioma 4
Adult Diffuse Astrocytoma 2
Idiopathic Parkinson Disease 2
Adult Giant Cell Glioblastoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluorodopa F18
Intervention Trials
Glioma 7
Glioblastoma 4
Astrocytoma 2
Oligodendroglioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluorodopa F18

Trials by Country

Trials by Country for Fluorodopa F18
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluorodopa F18
Location Trials
Minnesota 4
Pennsylvania 3
Texas 2
Arizona 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluorodopa F18

Clinical Trial Phase

Clinical Trial Phase for Fluorodopa F18
Clinical Trial Phase Trials
Phase 2 5
Phase 1 3
N/A 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluorodopa F18
Clinical Trial Phase Trials
Active, not recruiting 4
Terminated 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluorodopa F18

Sponsor Name

Sponsor Name for Fluorodopa F18
Sponsor Trials
National Cancer Institute (NCI) 5
Mayo Clinic 4
Erik Mittra 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluorodopa F18
Sponsor Trials
Other 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Baxter
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.